Human milk remains biochemically altered after mastitis symptoms fade
Lactational mastitis can interrupt breastfeeding with pain and inflammation, but the more clinically difficult question often comes after the flare settles: does milk return to a fully normal biologic state once symptoms improve? In this study, milk collected during the remission period of lactational mastitis did not show major shifts in overall microbiome diversity, yet the metabolomic and lipidomic profile remained distinctly altered compared with control mothers.
That split between microbial stability and lipid disruption matters at the bedside. A mother may feel clinically better and assume the breast has fully reset, while the milk still carries evidence of a perturbed inflammatory and metabolic milieu.
Investigators used 16S rRNA sequencing to profile the microbiome and LC–MS/MS to examine the untargeted metabolome and lipidome in milk from women with lactational mastitis in remission and from control mothers. Across the microbial datasets, alpha diversity and beta diversity were not significantly different between the two groups. The genera often linked with mastitis, including Staphylococcus and Streptococcus, also did not differ significantly in this remission-phase comparison.
The biological message is reassuring on one level and incomplete on another. The milk did not appear to remain overtly dysbiotic by broad community metrics, but the chemical composition of that milk still carried a disease signature.
Lipid signatures carried the strongest signal
The clearest differences emerged in the lipidome. Significant shifts were seen in the abundance of metabolites, with enrichment in several important lipid classes, including ceramides, triglycerides, O-acyl-hydroxy fatty acids, phosphatidylcholine, and lysophosphatidylcholine. These are not trivial background findings. Lipids in human milk are central to infant nutrition, membrane biology, and immune signaling, and they also reflect the mother’s local breast physiology.
Two pathways stood out in the KEGG analysis: arachidonic acid metabolism and α-linolenic acid metabolism. Both sit within fatty acid networks that influence inflammatory signaling and membrane remodeling. Arachidonic acid metabolism is especially relevant because it feeds into eicosanoid biology, a pathway closely tied to inflammatory tone and tissue recovery. α-Linolenic acid metabolism, by contrast, connects to polyunsaturated fatty acid handling and broader lipid homeostasis, suggesting that the breast tissue environment may still be recalibrating after the acute mastitis episode.
Even in remission, the milk chemistry does not read as entirely neutral.
Why a normal microbiome does not equal a normal milk profile
The absence of major microbiome differences could tempt clinicians to conclude that the breast has fully normalized once symptoms resolve. The lipid data argue for more caution. Milk is a complex secretory fluid, and its biology is shaped not only by bacterial communities but also by epithelial metabolism, local immune activity, and lipid trafficking within mammary tissue. A breast that has recently undergone inflammation may restore microbial balance before it fully restores lipid synthesis and turnover.
Ceramides and lysophospholipids are particularly interesting in this context. Ceramides often participate in stress and inflammatory signaling, while phosphatidylcholine and lysophosphatidylcholine are major membrane and lipid-transport components that can shift when tissue metabolism changes. A change in these species suggests ongoing metabolic remodeling, even if conventional microbial markers look stable.
For breastfeeding counseling, that distinction is clinically useful. The study does not show that milk in remission is unsafe, nor does it demonstrate a need to stop breastfeeding after mastitis resolves. Instead, it shows that biochemical recovery may lag behind symptom recovery, which is an important difference for future research and for how remission is biologically understood.
What this study does and does not prove
This was an omics study, not a clinical outcomes trial. It identified differences in milk composition but did not link those differences to infant growth, infant illness, maternal recurrence risk, or future breastfeeding success. It also did not establish whether the lipid abnormalities normalize with longer follow-up or whether they predict another mastitis episode.
Those unanswered questions are not minor. If lipid dysregulation persists after symptom resolution, the next practical issue is whether that signal reflects residual inflammation, incomplete tissue repair, altered milk synthesis, or a transient post-illness state that resolves without intervention. None of those possibilities can be separated from the current data alone.
The study design still offers a useful clinical frame. Women in remission were not simply described as “recovered” and left unexamined; their milk was interrogated at a molecular level, and the results suggest that breast recovery is more layered than symptom disappearance suggests. Microbial diversity may normalize quickly, while lipid metabolism remains perturbed.
Breastfeeding counseling after mastitis needs a biologic, not just symptom-based, lens
For clinicians managing lactational mastitis, the study supports a practical message: remission should not be treated as biologic erasure. The breast may no longer be painful or inflamed to the patient, but the milk can still reflect a metabolically active healing phase. That has implications for future work on lactation recovery, breast inflammation, and the nutritional or immunologic consequences of altered milk lipids.
It also reinforces why a single clinical milestone rarely captures the full biology of mastitis. Symptom resolution, microbiome stability, and lipid normalization may not happen on the same timeline. In this cohort, the microbial readout looked comparatively quiet, while the lipid profile remained visibly changed.
The study leaves one concrete gap: whether these lipid abnormalities persist long enough to matter clinically, or whether they are simply a transient biochemical residue of recent inflammation. Until that is answered, lactational mastitis in remission should be viewed as a state of apparent recovery with measurable molecular aftereffects.